Mark Bloemendaal

Mark Bloemendaal is the CEO and Founder of Angiogenesis Analytics, specializing in prostate cancer detection using ultrasound. Mark also serves as an Advisor for Signal processing and Artificial Intelligence at NLC - The Healthtech Venture Builder and LivAssured BV. Mark previously founded and led SmartRollout and Implementation IQ, focusing on improving healthcare quality, safety, and affordability through innovative solutions. With a background in Electrical Engineering and an MBA, Mark is currently pursuing a PhD at Utrecht University in the application of Artificial Intelligence in Healthcare.